Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs ResMed Inc. — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.56, while ResMed Inc. trades at $194.03 (market cap $28.81B). The key difference: ResMed Inc. pays a 1.21% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| IEI | RMD | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $120.72 | $293.73 |
52-Week Low | $116.45 | $182.82 |
Market Cap | — | $28.81B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.76, down 0.19% with a bearish technical signal from moving averages. The ETF focuses on intermediate-term U.S. Treasury bonds, offering lower volatility compared to corporate bond alternatives. Recent news highlights institutional selling by AlTi Global Inc. and competitive pressure from Vanguard's lower-cost bond ETFs.
The outlook remains cautious amid Federal Reserve uncertainty and rising inflation concerns. While Treasury ETFs provide safety during market stress, IEI faces headwinds from potential rate hikes and stronger-yielding alternatives. Key risks include interest rate sensitivity and investor preference for higher-yield bond options in the current environment.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
